Execution has its rewards, and Alnylam Pharmaceuticals (NASDAQ: ALNY ) continues to justify my thesis that this is one of the best all-around biotechs in the field, as the company continues to couple well above-averageAnalyst’s Disclosure:I/we have a beneficial long position in the shares of ALNY, RHHBY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no ...